134 related articles for article (PubMed ID: 37659025)
1. Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
Target Oncol; 2023 Sep; 18(5):639-641. PubMed ID: 37659025
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
Lancet; 2023 Mar; 401(10379):821-832. PubMed ID: 36774933
[TBL] [Abstract][Full Text] [Related]
3. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
[TBL] [Abstract][Full Text] [Related]
5. A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma.
Kato R; Kojima T; Sazuka T; Yamamoto H; Fukuda S; Yamana K; Sugino Y; Hamamoto S; Nakaigawa N; Kabu K; Murakami H; Obara W
Anticancer Res; 2021 Dec; 41(12):6199-6209. PubMed ID: 34848474
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.
Wu B; Zhang Q; Sun J
J Immunother Cancer; 2018 Nov; 6(1):124. PubMed ID: 30458884
[TBL] [Abstract][Full Text] [Related]
7. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
Motzer RJ; Choueiri TK; McDermott DF; Powles T; Vano YA; Gupta S; Yao J; Han C; Ammar R; Papillon-Cavanagh S; Saggi SS; McHenry MB; Ross-Macdonald P; Wind-Rotolo M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35304405
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
[TBL] [Abstract][Full Text] [Related]
9. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
[TBL] [Abstract][Full Text] [Related]
10. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
12. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.
Kobayashi Y; Arai H; Honda M
Curr Oncol; 2020 Aug; 27(4):225-228. PubMed ID: 32905370
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
[TBL] [Abstract][Full Text] [Related]
16. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
[TBL] [Abstract][Full Text] [Related]
17. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
[TBL] [Abstract][Full Text] [Related]
18. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma.
Kuusk T; Bex A
Hematol Oncol Clin North Am; 2023 Oct; 37(5):907-920. PubMed ID: 37369611
[TBL] [Abstract][Full Text] [Related]
20. Editorial Comment on "Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma".
Teishima J
Int J Urol; 2023 Sep; 30(9):752-753. PubMed ID: 37218357
[No Abstract] [Full Text] [Related]
[Next] [New Search]
